Prescription medicine
Etripamil Brand names: Cardamyst
Etripamil (Cardamyst) is a prescription medicine with an FDA approval on record since 2025. No generic is listed; pharmacies paid $790.10 per unit (Cardamyst 70 mg nasal spray) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the etripamil FDA label on DailyMed (effective December 8, 2025, Milestone Pharmaceuticals USA, Inc.); the NDA 218571 record on Drugs@FDA; every etripamil label on DailyMed.
Highlights of the record
FDA label of December 8, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageCARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Forms and strengths
- 70 mg/.2ml
Spray.
On the market
- Earliest approval on file
- December 12, 2025 Cardamyst, Milestone Pharms Usa; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- July 15, 2042 Cardamyst spray; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $790.10 per unit Cardamyst 70 mg nasal spray
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is etripamil used for?
From the label: indications and usageCARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST is a calcium channel blocker indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults ( 1 ).
Source: FDA drug label (Cardamyst), Milestone Pharmaceuticals USA, Inc., effective December 8, 2025 (SPL set a92170b9-4f93-4b83-b2cd-cb85c52821cd), via openFDA; the full label on DailyMed
Is there a generic for etripamil (Cardamyst)?
No generic etripamil is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 6 patents for Cardamyst spray: the compound patent runs to June 19, 2028, and the last listed entry to July 15, 2042. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2025 earliest approval on file
- 2042 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for etripamil (Cardamyst)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $790.10 per unit (Cardamyst 70 mg nasal spray). NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Cardamyst 70 mg nasal spray | Brand | $790.10 per unit | n/a | n/a |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Check an interaction
- what two or more labels say about each other